Korro Announces $70 Million Private Placement
April 18, 2024 08:30 ET
|
Korro Bio, Inc.
Financing led by Deep Track Capital with participation from other leading healthcare investors Pro-forma cash and cash equivalents of approximately $236 million before fees and expenses On track for...
Korro to Participate in Upcoming Investor Conferences
April 01, 2024 16:01 ET
|
Korro Bio, Inc.
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., Chief Financial Officer,...
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
March 26, 2024 16:01 ET
|
Korro Bio, Inc.
On track for regulatory filing for First-in-Human study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024Demonstrated the versatility of Korro’s RNA...
Korro to Present at the TD Cowen 44th Annual Health Care Conference
February 27, 2024 08:00 ET
|
Korro Bio, Inc.
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., will present at the TD Cowen...
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio
January 18, 2024 08:00 ET
|
Korro Bio, Inc.
KRRO-110 has a potentially best-in-class profile with secretion of ~50µM functional AAT protein after a single dose in a preclinical mouse modelEvidence of greater than 40% editing of SERPINA1 RNA in...
Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024 08:00 ET
|
Korro Bio, Inc.
CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., will present at the 42nd...
Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
December 07, 2023 08:00 ET
|
Korro Bio, Inc.
KRRO-110 is the first RNA editing oligonucleotide candidate from Korro’s proprietary OPERA™ platform Korro has demonstrated the ability to repair the misfolding of the Alpha-1 Antitrypsin (A1AT)...
Korro Bio Appoints Dr. Rachel Meyers to Board of Directors
November 28, 2023 08:00 ET
|
Korro Bio, Inc.
Biotech veteran brings more than two decades of life science experience to Korro’s Board CAMBRIDGE, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a...
UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
November 03, 2023 15:31 ET
|
Korro Bio, Inc.
Korro will be focused on advancing a wholly owned portfolio of RNA editing programsPost-transaction cash of approximately $170 million expected to fund operations into 2026Funds multiple potentially...
Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
November 03, 2023 12:19 ET
|
Korro Bio, Inc.
Korro will be focused on advancing a wholly owned portfolio of RNA editing programsPost-transaction cash of approximately $170 million expected to fund operations into 2026Funds multiple potentially...